Ionis Pharmaceuticals (IONS) Stock News

Ionis Pharmaceuticals (Nasdaq: IONS) has announced its participation in three upcoming investor conferences in September 2025. The company's management will engage in fireside chats at the 2025 Wells Fargo Healthcare Conference (September 4), the H.C. Wainwright 27th Annual Global Investment Conference (September 8), and the Morgan Stanley 23rd Annual Global Healthcare Conference (September 9).

Investors can access live webcasts of these presentations through the Investors & Media section of Ionis's website. Replay recordings will be available within 48 hours and archived for a limited time.

Ionis Pharmaceuticals (NASDAQ:IONS) announced breakthrough results from Phase 3 CORE and CORE2 studies of olezarsen in treating severe hypertriglyceridemia (sHTG). The drug demonstrated a 72% placebo-adjusted reduction in fasting triglycerides and an unprecedented 85% reduction in acute pancreatitis events (p=0.0002).

The largest pivotal program for sHTG, involving nearly 1,100 patients, showed significant efficacy at both 80mg and 50mg monthly doses. The drug maintained a favorable safety profile, with over 90% of patients choosing to continue in the open-label extension study. Ionis plans to submit a supplemental new drug application (sNDA) by year-end.

Additionally, Phase 3 Essence study results for moderate hypertriglyceridemia were published in The New England Journal of Medicine, demonstrating significant triglyceride reduction and meeting all key secondary endpoints.

Ionis Pharmaceuticals (Nasdaq: IONS) has received FDA approval for DAWNZERA™ (donidalorsen), the first RNA-targeted prophylactic treatment for hereditary angioedema (HAE) in patients 12 years and older. The drug demonstrated an 81% reduction in monthly HAE attack rates compared to placebo in Phase 3 trials, increasing to 87% from the second dose.

DAWNZERA offers the longest dosing interval available, administered via subcutaneous autoinjector every 4 or 8 weeks. The treatment showed a 94% total mean attack rate reduction after one year in extension studies. Notably, 84% of patients preferred DAWNZERA over prior treatments, citing better disease control and improved administration experience.

This marks Ionis' second independent product launch in nine months, with DAWNZERA becoming commercially available in the coming days, supported by the Ionis Every Step™ patient support program.

Ionis Pharmaceuticals (Nasdaq: IONS) reported strong Q2 2025 financial results, with total revenue doubling to $452 million compared to $225 million in Q2 2024. The company's TRYNGOLZA™ generated $19 million in net product sales in Q2 2025. Based on strong performance, Ionis increased its 2025 financial guidance, now expecting total revenue of $825-850 million, up from previous guidance of $725-750 million.

Key upcoming catalysts include the anticipated approval of donidalorsen for hereditary angioedema (HAE) next month and Phase 3 data from the CORE and CORE2 studies in severe hypertriglyceridemia expected in September 2025. The company's partnered medicine WAINUA™ generated $44 million in Q2 sales, while SPINRAZA® contributed $54 million in royalty revenue.

Ionis Pharmaceuticals (Nasdaq: IONS) and Sobi® announced that the European Medicines Agency's CHMP has recommended approval for TRYNGOLZA® (olezarsen) to treat familial chylomicronemia syndrome (FCS) in the EU. The decision follows successful Phase 3 Balance study results showing significant triglyceride reductions and fewer acute pancreatitis events.

The treatment demonstrated sustained triglyceride reduction over 12 months with favorable safety. FCS, affecting up to 13 people per million in the EU, is a rare genetic condition causing severe hypertriglyceridemia with triglyceride levels often exceeding 880 mg/dL. The European Commission's final approval decision is expected by Q4 2025.

Sobi will handle commercialization outside the U.S., Canada, and China, leveraging their existing market expertise from Waylivra. TRYNGOLZA was previously approved in the U.S. in December 2024.

Ionis Pharmaceuticals (Nasdaq: IONS) announced positive Phase 3 OASISplus study results for donidalorsen in hereditary angioedema (HAE) patients, published in JACI In Practice. The study demonstrated that patients switching from other prophylactic treatments to donidalorsen experienced a 62% further reduction in mean monthly HAE attack rate from baseline.

Key findings include 84% of patients preferring donidalorsen over prior treatments, with 93% reporting well-controlled disease compared to 67% at baseline. The drug showed positive results across different prior treatments, with attack rate reductions of 65%, 41%, and 73% for patients switching from lanadelumab, C1INH, and berotralstat, respectively.

Donidalorsen is currently under FDA review with a PDUFA date of August 21, 2025, positioning it as a potential first-in-class prophylactic treatment for HAE in patients 12 years and older.

Ionis Pharmaceuticals (Nasdaq: IONS) has announced it will host a webcast to discuss its second quarter 2025 financial results and provide updates on key programs. The event is scheduled for Wednesday, July 30th at 11:30 a.m. Eastern Time.

Investors and interested parties can access the webcast through the company's investor relations website at ir.ionis.com. A replay of the presentation will be made available for a limited time following the event.

Ionis Pharmaceuticals (NASDAQ:IONS) announced positive interim Phase 1 results for salanersen (ION306/BIIB115), their novel antisense oligonucleotide for treating spinal muscular atrophy (SMA). The drug, licensed to Biogen, showed promising results with once-yearly dosing potential.

Key findings include 70% reduction in neurofilament light chain at 6 months, sustained through one year. In a subgroup of 8 participants aged 2-12, half achieved new WHO motor milestones, with mean improvements of 3.3 points in HFMSE and 5.3 points in RULM. Both tested doses (40mg and 80mg) were generally well-tolerated.

Based on these positive results, Biogen is engaging with global regulators to advance salanersen to Phase 3 studies.

Ionis Pharmaceuticals announced that Dr. Richard Geary, Executive VP and Chief Development Officer, will retire in January 2026 after a 30-year tenure. Dr. Holly Kordasiewicz, currently SVP of Neurology, will succeed him. During his tenure, Dr. Geary led numerous development programs resulting in six FDA and EU approvals, including TRYNGOLZA. Dr. Kordasiewicz, with 20 years of R&D experience, currently oversees Ionis' neurology program, which includes eight wholly owned medicines in clinical development. She played a key role in developing QALSODY for ALS and IONIS-MAPTRx for Alzheimer's disease. Dr. Geary will continue as a strategic consultant throughout 2026 to ensure a smooth transition.